Outcomes for olfactory neuroblastoma treated with induction chemotherapy.

Authors :: Su SY
Bell D
Ferrarotto R
Phan J
Roberts D
Kupferman ME
Frank SJ
Fuller CD
Gunn GB
Kies MS
Glisson BS
Hanna EY
Source :: Head & neck [Head Neck] 2017 Aug; Vol. 39 (8), pp. 1671-1679. Date of Electronic Publication: 2017 May 31.
Publication Year :: 2017
Abstract: Background: Oncologic outcomes for induction chemotherapy and its role in patients with advanced olfactory neuroblastoma (ONB) remain unclear.<br />Methods: A retrospective review of 15 consecutive patients with extensive local invasion and/or nodal disease treated with induction chemotherapy with curative intent followed by definitive local therapy.<br />Results: The majority of patients were treated with cisplatin and etoposide. The response to chemotherapy was 68% (10/15). Response was 78% (7/9) in the high Hyams high-grade group and 50% (3/6) in the Hyams low-grade group. Seven patients had complete response (CR) and 3 patients were able to avoid orbital exenteration. The 5-year disease-free survival (DFS) and overall survival (OS) were 71% and 78%, respectively, with a trend toward improved survival in patients with CR.<br />Conclusion: ONB is a chemosensitive tumor and induction chemotherapy is an acceptable strategy for aggressive and locoregional advanced disease. Hyams grade may predict chemosensitivity and CR may be associated with improved survival.<br /> (© 2017 Wiley Periodicals, Inc.)